FINWIRES · TerminalLIVE
FINWIRES

$AMLX

12 stories mentioning AMLXUpdated 35d ago

Every FINWIRES story that references AMLX, newest first.

What are analysts saying about AMLX?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on AMLX?

Sectors

Sector Update: Healthcare Stocks Climb Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.8%.The iShares Biotechnology ETF (IBB) was up 1%.In corporate news, Haemonetics (HAE) shares jumped past 16% after the company said it entered into a supply agreement with CSL Plasma last week.Pfizer (PFE) was Smart Insider's stock pick of the week after Chief Executive and Chair Albert Bourla bought 38,000 shares for $1 million at $26.34 apiece on Aug. 12. Bourla, who has been with Pfizer since 1993 and has served as CEO since January 2020, increased his holding by 10% to $11.6 million with his first reported purchase, Smart Insider said in a Tuesday note. Pfizer shares rose 1.5%.Amylyx Pharmaceuticals (AMLX) shares surged 63% after the company said Tuesday its investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 trial.GE HealthCare (GEHC) has appointed William Grogan as chief financial officer, effective Sept. 14, the company said Tuesday. Grogan succeeds Jay Saccaro, who stepped down to pursue another opportunity outside the medical technology industry, the company said. GE HealthCare shares were up 0.6%.

$AMLX$GEHC$HAE$PFE
Wire

Top Midday Gainers

Xos (XOS) signed an agreement with the US Air Force to develop and deliver a deployable mobile charging solution for electrified support equipment and vehicles, the company said late Monday.Shares more than doubled as intraday trading volume catapulted to over 96.8 million from a daily average of more than 3 million.Amylyx Pharmaceuticals' (AMLX) investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 trial, the company said Tuesday.Shares surged 55% as intraday trading volume soared to over 18.4 million from a daily average of roughly 1.68 million.FORT Robotics plans to go public through a business combination with Newbury Street II Acquisition (NTWO), a blank-check company, the companies said Tuesday.The transaction values the combined company at a pro-forma enterprise value of $556.6 million, the companies said.Shares jumped 11%, with intraday trading volume at over 10.4 million.Price: $4.31, Change: $+2.22, Percent Change: +106.22%

$AMLX$NTWO$XOS
Sectors

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, Amylyx Pharmaceuticals (AMLX) shares surged nearly 55% after the company said Tuesday its investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 trial.Pfizer (PFE) was Smart Insider's stock pick of the week after Chief Executive and Chair Albert Bourla bought 38,000 shares for $1 million at $26.34 apiece on Aug. 12. Bourla, who has been with Pfizer since 1993 and has served as CEO since January 2020, increased his holding by 10% to $11.6 million with his first reported purchase, Smart Insider said in a Tuesday note. Pfizer shares rose 1.4%.GE HealthCare (GEHC) has appointed William Grogan as chief financial officer, effective Sept. 14, the company said Tuesday. Grogan succeeds Jay Saccaro, who stepped down to pursue another opportunity outside the medical technology industry, the company said. GE HealthCare shares were up 0.6%.

$AMLX$GEHC$PFE
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, Amylyx Pharmaceuticals (AMLX) shares surged nearly 55% after the company said Tuesday its investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 trial.

$AMLX
Wire

Top Midday Stories: Home Depot Q2 EPS, Revenue Top Estimates; Klarna Cuts Guidance, Plans CFO, CMO Transitions

All three major US stock indexes were down in late-morning trading Tuesday, as the yield on the US 30-year Treasury topped 5.33%, a 19-year high, on long-term inflation and debt concerns.In company news, Home Depot (HD) reported fiscal Q2 adjusted earnings Tuesday of $4.92 per diluted share, up from $4.68 a year earlier and above the FactSet consensus analyst estimate of $4.73. Fiscal Q2 net sales were $47.86 billion, up from $45.28 billion a year ago and above the FactSet consensus of $47.24 billion. Separately, the company said it has launched nationwide express delivery to provide product fulfillment in three hours or less for a flat fee. The service does not require a subscription or membership and uses more than 2,000 store locations in the US as fulfillment hubs to deliver construction materials and tools directly to homes or job sites, the company said. Home Depot shares were up 0.8% around midday.Klarna Group (KLAR) reported Q2 EPS of $0.01, swinging from a loss of $0.14 a year earlier and above the FactSet consensus of a loss of $0.06. Second-quarter revenue was $1.04 billion, up from $823 million a year ago and above the FactSet consensus of $996.5 million. For Q3, the company expects revenue of $940 million to $980 million, below the FactSet consensus of $1.11 billion. For full-year 2026, Klarna expects revenue of $4.08 billion to $4.16 billion, down from its prior outlook of greater than $4.34 billion and below the FactSet consensus of $4.42 billion. In addition, Klarna said it has planned transitions for its chief financial officer and chief marketing officer, effective early 2027. CFO Niclas Neglen and CMO David Sandstrom will remain in their roles through the transition, the company said, adding that a search for a New York-based CFO is underway. Klarna shares were down 21.7%.Walt Disney (DIS) and its ABC unit sued the US Federal Communications Commission on Tuesday to block an early review of broadcast licenses for eight ABC stations, according to multiple media reports, which cited a lawsuit filed in a Washington, D.C. federal court. Disney shares were up 1%.Amylyx Pharmaceuticals' (AMLX) investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 clinical trial, the drugmaker said Tuesday. The drug showed a 55% reduction in the composite rate of level 2 and 3 hypoglycemic events compared to a placebo and also met all secondary endpoints in the 78-patient trial, the company said. Amylyx shares were up 48%.KKR (KKR) has offered to buy natural-gas and electricity distributor UGI (UGI) for $42.50 a share, or roughly $9 billion, The Wall Street Journal reported Tuesday, citing people familiar with the matter. KKR shares were down 1.2%, while UGI shares were up 12.5%.Baidu (BIDU) reported Q2 non-GAAP earnings Tuesday of 7.22 Chinese renminbi ($1.06) per diluted American depositary share, down from 13.58 renminbi a year earlier and below the FactSet consensus of $9.35 renminbi. Second-quarter revenue was 31.33 billion renminbi, down from 32.71 billion renminbi a year ago and below the FactSet consensus of 31.78 billion renminbi. Baidu shares were down more than 12%.Price: $15.28, Change: $-4.23, Percent Change: -21.66%

$AMLX$BIDU$DIS$HD$KKR$KLAR$UGI
Wire

Stifel Nicolaus Adjusts Amylyx Pharmaceuticals Price Target to $45 From $21, Maintains Buy Rating

Amylyx Pharmaceuticals (AMLX) has an average rating of buy and mean price target of $27.53, according to analysts polled by FactSet.Price: $32.65, Change: $+11.22, Percent Change: +52.33%

$AMLX
Sectors

Sector Update: Healthcare Stocks Flat to Higher Premarket Tuesday

Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7%.Amylyx Pharmaceuticals (AMLX) shares rose more than 34% after the company said its investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 clinical trial.Immatics (IMTX) stock was down more than 4% after the company reported a wider-than-expected Q2 net loss, as revenue also missed analysts' estimates.BlossomHill Therapeutics (BLSM) shares were up more than 3% after the company said the US FDA has granted fast track designation for BH-30643 in advanced or metastatic non-small cell lung cancer following prior treatment with a third-generation EGFR tyrosine kinase inhibitor.

$AMLX$BLSM$IBB$IMTX$XLV
Commodities

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Tuesday Amid Rising Oil Prices

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4%, and the actively traded Invesco QQQ Trust (QQQ) was 1.2% lower in Tuesday's premarket activity as fading hopes for a US-Iran peace agreement pushed oil prices higher.US stock futures were mixed, with S&P 500 Index futures down 0.5%, Dow Jones Industrial Average futures advancing 0.03%, and Nasdaq futures slipping 1.2% before the start of regular trading.July housing starts fell by 12.4% from the previous month to a 1.239 million annual rate, compared with expectations compiled by Bloomberg as of 7:45 am ET for a 1.345 million rate after an increase to 1.415 million in June.The New York Federal Reserve's services index fell to 0.5 in August from 8.7 in July, compared with the expectations of a smaller decrease to a reading of 4.6 in a survey compiled by Bloomberg.Industrial production data for July will be released at 9:15 am ET, followed by the pending home sales data for July at 10 am ET.In premarket action, bitcoin was down by 0.04%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.1% lower, Ether ETF (EETH) retreated 0.4%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.3%, the Vanguard Health Care Index Fund (VHT) was down 0.4%, while the iShares US Healthcare ETF (IYH) was 2% higher. The iShares Biotechnology ETF (IBB) was 0.2% lowerAmylyx Pharmaceuticals' (AMLX) stock was up more than 30% premarket after the company said its investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 clinical trial.Winners and Losers:FinancialThe State Street Financial Select Sector SPDR ETF (XLF) was up 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.8%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.8% lower.Klarna Group (KLAR) shares were down more than 17% after the company said it has planned transitions for its chief financial officer and chief marketing officer, effective early 2027.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.8%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) gained 1.2%, and the iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.1%. The VanEck Retail ETF (RTH) was 0.3% lower, while the State Street SPDR S&P Retail ETF (XRT) was 0.1% higher.Baidu (BIDU) shares were down more than 7% pre-bell after the company reported lower Q2 non-GAAP earnings and revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.2%, the Vanguard Industrials Index Fund (VIS) was down 0.1%, and the iShares US Industrials ETF (IYJ) was inactive.Stantec (STN) stock was up 1% after the company said it received approval from the Toronto Stock Exchange to increase the number of shares it may repurchase for cancellation under its normal course issuer bid to 5.7 million shares, up from 2.3 million.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 1.8%, the iShares US Technology ETF (IYW) was 1.1% lower, and the iShares Expanded Tech Sector ETF (IGM) was down 1.6%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) declined 3.4%, while the iShares Semiconductor ETF (SOXX) fell 3.6%.NVIDIA (NVDA) shares were down 1% in premarket activity after the company said it partnered with SB Energy to secure land, power, and shell capacity at the PORTS-Pike Technology Campus in Ohio, where OpenAI will be the tenant.EnergyThe iShares US Energy ETF (IYE) was up 0.3%, while the State Street Energy Select Sector SPDR ETF (XLE) was 0.9% higher.Phillips 66 (PSX) stock was 1% higher after Argus lifted its price target to $269 from $197.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.9% to reach $85.27 per barrel on the New York Mercantile Exchange. Natural gas was up 0.9% at $2.71 per 1 million British Thermal Units. The United States Oil Fund (USO) increased 0.5%, while the United States Natural Gas Fund (UNG) was 0.02% lower.Gold futures for November were down by 0.6% at $4,448.00 an ounce on the Comex. Silver futures retreated 1.7% to $65.11 an ounce. SPDR Gold Shares (GLD) declined by 0.6%, and the iShares Silver Trust (SLV) was 1.1% lower.

Dow JonesNasdaq CompositeS&P 500$AMLX$BETH$BIDU$BITO$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$KLAR$NVDA$PMR$PSX$QQQ$RTH$SLV$SOXX$SPY$STN$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare

Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7%.Amylyx Pharmaceuticals (AMLX) shares were up more than 38% after the company said its investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 clinical trial.

$AMLX
Wire

Amylyx Pharmaceuticals Shares Rise After Q2 Loss Narrows

Amylyx Pharmaceuticals (AMLX) shares were up 9.3% in Thursday trading after the company's net loss narrowed in Q2.The company reported a quarterly net loss of $0.39 per diluted share, narrowing from a loss of $0.46 a year earlier.Analysts polled by FactSet expected a loss of $0.36.The company had cash, cash equivalents, and short-term investments of $250.8 million at June 30, expecting a cash runway into 2028.Price: $23.87, Change: $+2.02, Percent Change: +9.24%

$AMLX
Wire

Mizuho Lifts Price Target on Amylyx Pharmaceuticals to $21 From $19, Maintains Outperform Rating

Amylyx Pharmaceuticals (AMLX) has an average rating of buy and mean price target of $23.30, according to analysts polled by FactSet.Price: $15.76, Change: $-0.55, Percent Change: -3.37%

$AMLX
Wire

Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $21 From $19, Maintains Outperform Rating

Amylyx Pharmaceuticals (AMLX) has an average rating of buy and mean price target of $23.30, according to analysts polled by FactSet.Price: $15.78, Change: $-0.53, Percent Change: -3.22%

$AMLX

Track with the FINWIRES app suite